StockData
BlossomHill Therapeutics, Inc. logo

BlossomHill Therapeutics, Inc. (BLSM) stock

BLSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$15.13+1.48 (+10.84%)

Close on Nov 17, 2026Market cap $38.56MP/E –Yield –

BlossomHill Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

No ebitda figures for BlossomHill Therapeutics

BlossomHill Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More BlossomHill Therapeutics figures

See a number that looks wrong?